Results 21 to 30 of about 775,670 (354)

Inhibiting epidermal growth factor receptor at a distance. [PDF]

, 2014
The epidermal growth factor receptor (EGFR) tyrosine kinase is implicated in a large number of human cancers. Most EGFR inhibitors target the extracellular, growth factor-binding domain or the intracellular, ATP-binding domain. Here we describe molecules
Denton, Elizabeth, Schepartz, Alanna, Sinclair, Julie   +2 more
core   +2 more sources

WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway [PDF]

, 2015
Stress exposure triggers ligand-independent EGF receptor (EGFR) endocytosis, but its post-endocytic fate and role in regulating signalling are unclear. We show that the p38 MAP kinase-dependent, EGFR tyrosine kinase (TK)-independent EGFR internalization ...
Burgoyne, T, Futter, CE, Hartley, JA, Hochhauser, D, Sorkin, A, Tomas, A, Vaughan, SO   +6 more
core   +1 more source

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

New England Journal of Medicine, 2019
BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
S. Ramalingam, J. Vansteenkiste, D. Planchard, B. Cho, J. Gray, Y. Ohe, Caicun Zhou, T. Reungwetwattana, Ying Cheng, B. Chewaskulyong, R. Shah, M. Cobo, K. Lee, P. Cheema, M. Tiseo, T. John, Meng-Chih Lin, F. Imamura, T. Kurata, A. Todd, R. Hodge, M. Saggese, Y. Rukazenkov, J. Soria   +23 more
semanticscholar   +1 more source

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities

International Journal of Molecular Sciences, 2023
Epidermal growth factor receptors (EGFRs) are a class of receptor tyrosine kinase that are also called ErbB1 and HER1. EGFR tyrosine kinase activity inhibition is considered a promising therapeutic strategy for the treatment of cancer.
Tanzida Zubair, D. Bandyopadhyay
semanticscholar   +1 more source

Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR [PDF]

Oncogene, 2012
Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast
Li, X, Lu, Y, Liang, K, Hsu, J -M., Albarracin, C, Mills, G B, Hung, M-C, Fan, Z   +7 more
openaire   +2 more sources

Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line. [PDF]

, 2019
BackgroundThe epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least
Ardell, David H, Eckert, Alexander W, Grosse, Ivo, Kappler, Matthias, Kotrba, Johanna, Vordermark, Dirk, Weinholdt, Claus, Wichmann, Henri   +7 more
core   +3 more sources

Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation [PDF]

Pharmaceutical Sciences
Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases.
Maedeh Yousefi, Hamed Farzi-Khajeh, Mostafa Akbarzadeh-Khiavi, Azam Safary, Khosro Adibkia   +4 more
doaj   +1 more source

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy [PDF]

, 2019
Introduction: There is substantial evidence for the onco- genic effects of fi broblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed speci fi cally in lung ...
Carnero Moya, Amancio, Cirauqui, Cristina, Conde, Esther, Enguita, Ana Belén, Ferrer, Irene, Marrugal, Ángela, Molina Pinelo, Sonia, Ojeda Márquez, Laura, Paz Ares, Luis, Ponce Aix, Santiago, Quintanal Villalonga, Álvaro Diego, Suárez, Rocío   +11 more
core   +1 more source

EGFR-TKIs resistance via EGFR-independent signaling pathways [PDF]

Molecular Cancer, 2018
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment.
Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu, Kongming Wu   +5 more
openaire   +3 more sources

Estimated glomerular filtration rate correlates poorly with four-hour creatinine clearance in critically ill patients with acute kidney injury. [PDF]

, 2013
Introduction. RIFLE and AKIN provide a standardised classification of acute kidney injury (AKI), but their categorical rather than continuous nature restricts their use to a research tool. A more accurate real-time description of renal function in AKI is
Kirwan, CJ, Macphee, IA, Philips, BJ
core   +2 more sources